Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Octreotide

Octreotide

pharmaceutical raw materials
Octreotide structure

Octreotide 

structure
  • CAS No:

    79517-01-4

  • Formula:

    C49H66N10O10S2

  • Chemical Name:

    Octreotide

  • Synonyms:

    SANDOSTATIN;SMS-201-995;[r-(r*,r*)]-d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-threonyl-n-[2-hydroxy-1-(hydroxy-methyl)propyl]-cysteinamide cyclic(2->7)-disulfide;OCTREOTIDE;OCTREOTIDE (SMS 201-995), ACETATE;cyclic(2-7)-disulfide,(r-l-threonyl-n-(2-hydroxy-1-(hydroxymethyl)propyl);d-phenylalanyl-l-cysteinyl-l-phenylalanyl-d-tryptophyl-l-lysyl-l-cysteinamid;r*))-(racetate(salt)

  • Categories:

    Active Pharmaceutical Ingredients  >  Hormones and the Endocrine System

Description

Octreotide acetate, a long-acting synthetic analog of native somatostatin, inhibits growth hormone, glucagon, and insulin more potently.

Octreotide Basic Attributes

1019.24

1018.440481

1308068-626-2

2937190000

Characteristics

382.82000

0.77

Colourless to off-white lyophilised solid

1.4±0.1 g/cm3

153-156°C

1447.2±65.0 °C at 760 mmHg

829.1±34.3 °C

1.673

H2O: soluble

−20°C

Intravenous-rat LD50: 18.1 mg/kg; Intravenous-mouse LD50: 72.3 mg/kg

Combustible; Fire site decomposes toxic nitrogen oxides, sulfur oxide fumes

D20 -42° (c = 0.5 in 95% acetic acid)

12.6None

Safety Information

NONH for all modes of transport

3

Treasury is low temperature, ventilated, dry; stored separately from food raw materials

|Warning|H315 (75%): Causes skin irritation [Warning Skin corrosion/irritation]|P261, P264, P271, P280, P302+P352, P304+P312, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, and P362|Aggregated GHS information provided by 4 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

highly toxic

Octreotide Use and Manufacturing

natural hormone somatostatin

Computed Properties

Molecular Weight:1139.3
Hydrogen Bond Donor Count:15
Hydrogen Bond Acceptor Count:18
Rotatable Bond Count:17
Exact Mass:1138.48273942
Monoisotopic Mass:1138.48273942
Topological Polar Surface Area:457
Heavy Atom Count:79
Complexity:1780
Defined Atom Stereocenter Count:2
Undefined Atom Stereocenter Count:8
Covalently-Bonded Unit Count:3
Compound Is Canonicalized:Yes

Drug Function and Efficacy

It can inhibit the pathological excessive secretion of growth hormone, thyroid-stimulating hormone, gastrointestinal and pancreatic endocrine hormones; it can selectively reduce the blood flow and pressure of the portal vein and its collateral circulation, and reduce the pressure of varicose veins in the esophagus and gastric fundus; it can inhibit gallbladder emptying and have a therapeutic effect on pancreatic lesions; it can inhibit the secretion of gastric acid and gastrin, and improve the blood supply to the gastric mucosa; it can inhibit gastrointestinal motility.

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

  • HYBIO PHARMACEUTICAL CO., LTD.

    European Union European Union
    Active
  • PolyPeptide Laboratories (Sweden) AB

    European Union European Union
    Active
  • CHENGDU SHENGNUO BIOPHARM CO., LTD.

    European Union European Union
    Active

Recommended Suppliers of Octreotide

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.